CareSource MAT and Drug Testing Coverage Update

Coverage Criteria for Drug Testing and MAT

Covered clinical criteria for drug testing and MAT

Covered when testing and MAT services meet clinical and documentation criteria:

Provider qualifications: MAT providers must be licensed in Arkansas and have a current X-DEA on file with Arkansas Medicaid; must follow SAMHSA guidelines, provide case management, coordinate follow-up/referrals, document monitoring and noncompliance, and not bill MAT prescribing for pain management under this policy.

[[chunk 4]]

Initial assessment and documentation: Initial evaluation for opioid use disorder must include history, medical and psychological assessment, appropriate lab screening for communicable diseases, informed consent and HIPAA-compliant communication, execution of a treatment agreement, development of a Person-Centered Service Plan (PCSP), identification of a MAT case manager, and a baseline individualized UDT.

[[chunk 6],[chunk 12]]

Follow-up frequency (first year): During the first year, require at least one follow-up MAT office visit per month for medication and treatment management, at least one independent clinical counseling visit or documented integrated follow-up per month, and drug testing in conjunction with each monthly visit.1/month

[[chunk 6],[chunk 7]]

Maintenance frequency (subsequent years): For maintenance (subsequent years), require regular outreach, at least one follow-up MAT office visit quarterly, drug testing in conjunction with each quarterly visit, and counseling as medically necessary with testing frequency decreasing as the member stabilizes.quarterly

[[chunk 7],[chunk 12],[chunk 11]]

OTP-specific requirements: For opioid treatment programs (OTP): maintenance treatment requires an initial toxicology plus 8 random UDT screens per year; short-term detoxification requires one initial UDT; long-term detoxification requires an initial and monthly random UDT(s).8/year for OTP maintenance

[[chunk 13]]

Test selection and use: Testing must be individualized to the member and analytes based on drugs of choice; use presumptive (qualitative) testing at the lowest level that informs care and reserve confirmatory/quantitative testing for unexpected results or when specific metabolite identification is required. Random-interval scheduling is recommended and providers should consider detection windows and cross-reactivity when selecting tests.

[[chunk 11],[chunk 13]]

Order content: Every drug test order must document type of test, clinical indication, diagnosis (ICD) and supporting diagnoses, drugs/drug classes to be tested, all current medications, physician's order and ordering IDs, signature/date of qualified provider, and include PCP PIN if referred by PCP; independent lab documentation must include the physician's order, test results, and all records pertinent to billing.

[[chunk 6]]

The following testing practices are considered not medically necessary and are excluded from coverage: reflexive, routine, standard, or preprinted orders and any testing that is not individualized to the member (for example, ordering all available tests from an instrument because a positive result is possible). Large arbitrary or wholesale panels, universal testing, custom profiles, standing orders, blanket orders, and routine nonspecific panels are not covered. Additionally, blood drug testing performed outside the emergency department and hair, saliva, or other non-urine body fluid testing for controlled substance monitoring are not medically necessary under this policy.

The policy explicitly lists types of testing that are not medically necessary, including testing required by third parties (for example, pre-employment or random employment testing, court-ordered testing for medico-legal purposes such as child custody, school entry/athletics/military testing, testing required by primary pay sources, residential program retention requirements, and physician health program monitoring). Also not covered are forensic testing, routine confirmatory testing following a negative presumptive result, and routine physical or administrative testing (e.g., marriage license or administrative purposes). Compliance with these exclusions may be enforced through post-payment audits and recovery actions.

Coding, Modifiers, and Billing Thresholds

Presumptive CPT CodesCPTCovered

80305	Presumptive drug testing (level varies) — billed one code per date of service
80307	Presumptive drug testing (higher complexity) — billed one code per date of service

MAT Modifiers referencedModifier

X2	Modifier indicating medication assisted treatment for opioid use disorder
X4	Modifier indicating medication assisted treatment for opioid use disorder

Medical necessity review threshold

In-network medical necessity review threshold$500 cumulative for members age ≥21 before a medical necessity review is required (unless MAT modifiers X2 or X4 are used)

Out-of-network/non-participating providersA review of medical necessity is required for all testing for non-participating/out-of-network providers

MAT modifier exceptionModifiers X2 or X4 billed to indicate MAT for opioid use disorder exempt in‑network members from the $500 threshold

Provider Requirements, Documentation, and Prior Authorization

Denial Risk

Denial Risk Overview

Providers should be aware that drug testing services may be denied when testing is performed without documentation that results will impact patient management, when confirmatory testing is ordered routinely (for example, reflexive confirmatory testing after a negative presumptive result), or when testing exceeds medical necessity review thresholds without prior authorization. Routine reflex confirmatory testing and blanket or standing orders for broad panels may lead to denials or recoupment if not justified in the medical record. Compliance may be monitored via post-payment analysis, medical review audits, recovery of overpayments, and prepay review.

Denials may occur if testing is for substances that would not affect patient management.
Routine reflex confirmatory testing following negative presumptive results is a denial risk unless clinically justified and documented.
Custom profiles, blanket orders, standing orders, or reflex testing without individualized justification increase audit and recoupment risk.
Lack of required laboratory CLIA documentation and failure to retain copies of orders and results can result in claim denials or recoupment.

Background

Drug testing supports diagnosis, monitoring, and recovery for members with substance use disorder or concern for diversion or misuse. Urine drug testing (UDT) can be performed as presumptive/qualitative testing to detect the presence of drug classes, with confirmatory/quantitative testing reserved for unexpected results or when identification of specific metabolites is required. Testing frequency and panel composition should be individualized based on the member’s treatment phase, prescribed medications, clinical history, and regional drug trends. For members in opioid treatment programs (OTP), federal regulations require an initial toxicology plus 8 random UDT screens per year for maintenance; short-term detoxification requires one initial UDT and long-term detoxification requires an initial and monthly random UDT. The policy emphasizes individualized test selection and documents that routine or blanket testing is not appropriate; custom profiles, standing orders, and routine confirmatory testing after a negative presumptive result are explicitly not medically necessary.

Key Definitions

Presumptive/Qualitative Test

DefinitionPresumptive/Qualitative Test: testing to determine chemical constituents (screening), e.g., commonly performed presumptive UDT methods

CPT codes80305 and 80307 — presumptive drug testing; may be billed one code per date of service

Billing noteValidity testing (e.g., urine specific gravity, creatinine, pH, oxidants) performed by the provider shall not be billed separately

Confirmatory/Quantitative Test

DefinitionConfirmatory/Quantitative Test: definitive testing that determines the amount of a substance per unit volume or weight; used for metabolite identification or unexpected results

Use caseReserved for unexpected presumptive results or when identification/quantification of specific opioids/metabolites is required

Level of Care: Outpatient, OTP, Maintenance

Outpatient / OTP / Maintenance

Admission context: Testing indicated prior to initiation or in early recovery, and for members who have relapsed; obtain a baseline individualized UDT and full assessment.

[[chunk 12]]

First year continuation: Monthly MAT visits, monthly drug testing, and monthly independent clinical counseling or documented integrated follow-up are required in the first year.1/month

[[chunk 6],[chunk 7]]

Maintenance continuation: Regular outreach to the member, at least one follow-up MAT office visit quarterly, drug testing in conjunction with each quarterly visit, and counseling as medically necessary in subsequent years; testing frequency should decrease as the member stabilizes.quarterly

Medication Assisted Treatment (MAT) Treatment Modalities

Medication Assisted Treatment (MAT)

MAT program requirements: MAT requires providers licensed in Arkansas with a current X-DEA on file, adherence to SAMHSA guidelines, case management, execution of treatment agreements, development of a Person-Centered Service Plan, coordination of counseling/referrals, and documentation of outreach and noncompliance actions.

[[chunk 4],[chunk 6]]

MAT Visit Frequency and Follow-up

MAT office visit

First-year frequencyAt least one (1) MAT office visit per month for medication and treatment management

Associated servicesDrug testing in conjunction with each monthly visit and at least one independent clinical counseling visit or documented integrated plan per month

DocumentationVisits must include signature/initials of physician, diagnoses, service dates and treatment plans as part of required records

MAT follow-up visit

Maintenance frequencyAt least one (1) MAT follow-up visit per quarter in subsequent (maintenance) years

Testing and counselingDrug testing should be performed in conjunction with each quarterly visit and counseling provided as medically necessary

OpenPayer

Drug testing and Medication Assisted Treatment (MAT) requirements for Arkansas PASSE